Loading...
XNAS
GRAL
Market cap3.66bUSD
Dec 04, Last price  
104.71USD
1D
3.47%
1Q
183.68%
IPO
515.91%
Name

Grail Inc

Chart & Performance

D1W1MN
XNAS:GRAL chart
P/E
—
P/S
29.15
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-23.68%
Rev. gr., 5y
%
Revenues
126m
+34.90%
00014,612,00055,550,00093,105,000125,595,000
Net income
-2.03b
L+38.30%
-275,718,000-244,855,000-312,156,000-1,247,775,000-5,399,098,000-1,465,685,000-2,027,005,000
CFO
-577m
L-3.13%
-209,260,000-245,794,000-232,002,000-688,130,000-561,313,000-595,800,000-577,156,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
URL
https://grail.com/
IPO date
Jun 12, 2024
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122023‑122022‑122022‑002021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT